Study on Sit to Quit Phone Intervention
Primary Purpose
Nicotine Dependence
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sit to Quit
Quit for Life
Sponsored by
About this trial
This is an interventional treatment trial for Nicotine Dependence focused on measuring Nicotine addiction, Cigarette smoking
Eligibility Criteria
Inclusion Criteria:
- Patient being treated at Duke Smoking Cessation Program for tobacco use
- Age 18 years or older
- Actively smoking 5 or more cigarettes per day for at least one year
- Fluency in spoken and written English
- Willing to set a quit date within 2 weeks
- Access to a smart phone or internet and telephone
- Willingness to watch 3 videos on computer, receive 5 counseling calls, and attend investigational visits.
Exclusion Criteria:
- CO test under 7 ppm during initial screening
- 8 or above on the Alcohol Use Disorders Identification Test (AUDIT-10)
- 6 or above on Drug Abuse Screening Test (DAST-10)
- 3 or above on Patient Health Questionnaire (PHQ-2) Depression Scale
- Daily use of a second form of tobacco or nicotine (e.g. e-cigarettes, cigars, chewing tobacco, snuff)
- Current use of a smoking cessation medication (e.g. nicotine replacement, Varenicline, Bupropion)
- Intolerable side effects related to, refusal to take, or medical contraindication with nicotine patch
- Symptomatic cognitive or emotive disorder such as untreated schizophrenia, severe untreated depression, or severe untreated anxiety. This is determined by clinical assessment.
Sites / Locations
- Duke Center for Smoking Cessation
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
North Carolina Quit Line: Quit for Life
Sit to Quit
Arm Description
Participants will be connected to the 'Quit for Life' program offered through the North Carolina Quit Line.
Participants will be connected to the 'Sit to Quit' program offered through the Duke Smoking Cessation Program.
Outcomes
Primary Outcome Measures
Biochemically confirmed continuous 30-day abstinence from smoking
Biochemically confirmed 30-day continuous abstinence. Abstinence is determined by a participant both reporting not smoking in the past 30 days AND a result of < 7 ppm in carbon monoxide breath testing. If the participant does not meet both criteria, they are not considered abstinent
Secondary Outcome Measures
Biochemically confirmed 7-day point prevalence abstinence from smoking
Biochemically confirmed 7-day continuous abstinence. Abstinence is determined by a participant both reporting not smoking in the past 7 days AND a result of < 7 ppm in carbon monoxide breath testing. If the participant does not meet both criteria, they are not considered abstinent
Biochemically confirmed 7-day point prevalence abstinence from smoking
Biochemically confirmed 7-day continuous abstinence. Abstinence is determined by a participant both reporting not smoking in the past 7 days AND a result of < 7 ppm in carbon monoxide breath testing. If the participant does not meet both criteria, they are not considered abstinent
Self-reported 7-day point prevalence abstinence rates
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Self-reported 7-day point prevalence abstinence rates
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Self-reported 7-day point prevalence abstinence rates
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Self-reported 7-day point prevalence abstinence rates
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Self-reported 7-day point prevalence abstinence rates
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Smoking reduction
Smoking reduction as measured by number of cpd measured by phone-based self-report
Smoking reduction
Smoking reduction as measured by number of cpd measured by phone-based self-report
Smoking reduction
Smoking reduction as measured by number of cpd measured by phone-based self-report
Smoking reduction
Smoking reduction as measured by number of cpd measured by phone-based self-report
Smoking reduction
Smoking reduction as measured by number of cpd measured by phone-based self-report
Changes in stress
Change in self-reported measures of stress
Changes in anxiety
Change in self-reported measures of anxiety
Changes in depression
Change in self-reported measures of depression
Changes in relapse predictors
Changes in self-reported measures on repeated non-standardized single-item question on stress, urges, and confidence assessed by phone
Feasibility: attendance records
Feasibility as measured by attendance and completion of STQ and QL assessed by attendance records taken instructors during phone sessions.
Feasibility: website usage
Feasibility as measured by website usage by electronically recording login and using a site-based timer to record time accessing the site through each intervention
Feasibility: course evaluation
Feasibility as measured by course evaluation
Feasibility: demographics
Feasibility as measured by demographics of patients at DSCP
Feasibility: Behavioral intervention used
Feasibility as measured by behavioral intervention assignment
Feasibility: Attendance at DSCP appointments
Feasibility as measured by attendance at DSCP appointments
Feasibility: Referral routes to DSCP
Feasibility as measured by referral routes to DSCP
Feasibility: Side effects
Feasibility as measured by side effects, as measured by phone assessment
Feasibility: medication adherence
Feasibility as measured by medication adherence, as measured by phone assessment
Feasibility: mindfulness practices
Feasibility as measured by non-standardized phone-based self-report of number of times mindfulness practices are used by experimental group
Feasibility: meditation time
Feasibility as measured by non-standardized phone-based self-report of time spent meditating by experimental group
Full Information
NCT ID
NCT02840435
First Posted
July 5, 2016
Last Updated
September 12, 2019
Sponsor
Duke University
Collaborators
Consumer Wellness Solutions, National Institute on Drug Abuse (NIDA)
1. Study Identification
Unique Protocol Identification Number
NCT02840435
Brief Title
Study on Sit to Quit Phone Intervention
Official Title
Pilot Study on Mindfulness Training for Smokers Via Web-based Video and Telephone Counseling
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
September 2016 (Actual)
Primary Completion Date
February 2018 (Actual)
Study Completion Date
June 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
Collaborators
Consumer Wellness Solutions, National Institute on Drug Abuse (NIDA)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designed to test the effectiveness of the smoking cessation intervention "Sit to Quit" through a randomized-control trial. This study will compare abstinence outcomes in the Sit to Quit study group to a control group using the North Carolina State Tobacco Quit Line.
Detailed Description
This study is designed to test the effectiveness of the smoking cessation intervention "Sit to Quit" through a randomized-control trial. This study will compare abstinence outcomes in the Sit to Quit study group to a control group using the North Carolina State Tobacco Quit Line. This is an investigational study (n=60) designed to test Sit to Quit (STQ) versus Quit Line (QL) through a pilot randomized control trial. The proposed study is designed with double-blind procedures (participants and study staff) for randomization of 60 participants recruited through Duke Smoking Cessation Program into two groups: STQ and QL. STQ participants will receive access to the STQ Instructional Video, the STQ manual, and proactive Quit Coach calls supporting STQ. QL participants will be instructed to contact the NC Quit Line and will receive access to "web Coach" (Alere Well-being site), the Quit Line manual, and proactive Quit Coach calls supporting "Quit for Life." All statistical analysis will be performed under the directions of the statistician designated in key personnel. Outcomes of variables including: demographic variables, evaluation responses, and abstinence rates will be analyzed using general regression models using an ANOVA-based design. The study Principal Investigator Dr. James Davis will ultimately be responsible for data and safety monitoring. Subject data will be collected during visits and captured in the Electronic Medical Record. Data will be collected by phone, and this data will be stored in REDCap. Participants that experience events related to their clinical treatment will be recommended to follow-up with their provider.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nicotine Dependence
Keywords
Nicotine addiction, Cigarette smoking
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
23 (Actual)
8. Arms, Groups, and Interventions
Arm Title
North Carolina Quit Line: Quit for Life
Arm Type
Active Comparator
Arm Description
Participants will be connected to the 'Quit for Life' program offered through the North Carolina Quit Line.
Arm Title
Sit to Quit
Arm Type
Experimental
Arm Description
Participants will be connected to the 'Sit to Quit' program offered through the Duke Smoking Cessation Program.
Intervention Type
Behavioral
Intervention Name(s)
Sit to Quit
Other Intervention Name(s)
Mindfulness Training for Smokers
Intervention Description
Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
Intervention Type
Behavioral
Intervention Name(s)
Quit for Life
Other Intervention Name(s)
North Carolina Quit Line
Intervention Description
Quit for Life integrates telephone counseling, written materials, NRT, and an online program called "Web Coach." Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the "Quit Guide," which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills.
Primary Outcome Measure Information:
Title
Biochemically confirmed continuous 30-day abstinence from smoking
Description
Biochemically confirmed 30-day continuous abstinence. Abstinence is determined by a participant both reporting not smoking in the past 30 days AND a result of < 7 ppm in carbon monoxide breath testing. If the participant does not meet both criteria, they are not considered abstinent
Time Frame
12 weeks post-Target Quit Day (TQD)
Secondary Outcome Measure Information:
Title
Biochemically confirmed 7-day point prevalence abstinence from smoking
Description
Biochemically confirmed 7-day continuous abstinence. Abstinence is determined by a participant both reporting not smoking in the past 7 days AND a result of < 7 ppm in carbon monoxide breath testing. If the participant does not meet both criteria, they are not considered abstinent
Time Frame
12 weeks post-TQD
Title
Biochemically confirmed 7-day point prevalence abstinence from smoking
Description
Biochemically confirmed 7-day continuous abstinence. Abstinence is determined by a participant both reporting not smoking in the past 7 days AND a result of < 7 ppm in carbon monoxide breath testing. If the participant does not meet both criteria, they are not considered abstinent
Time Frame
2 weeks post-TQD
Title
Self-reported 7-day point prevalence abstinence rates
Description
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Time Frame
1 week post TQD
Title
Self-reported 7-day point prevalence abstinence rates
Description
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Time Frame
12 weeks post TQD
Title
Self-reported 7-day point prevalence abstinence rates
Description
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Time Frame
26 weeks post TQD
Title
Self-reported 7-day point prevalence abstinence rates
Description
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Time Frame
6 weeks post TQD
Title
Self-reported 7-day point prevalence abstinence rates
Description
7-day point prevalence abstinence as measured by phone-based, single-item self-report
Time Frame
2 weeks post TQD
Title
Smoking reduction
Description
Smoking reduction as measured by number of cpd measured by phone-based self-report
Time Frame
1 week post-TQD
Title
Smoking reduction
Description
Smoking reduction as measured by number of cpd measured by phone-based self-report
Time Frame
2 weeks post-TQD
Title
Smoking reduction
Description
Smoking reduction as measured by number of cpd measured by phone-based self-report
Time Frame
6 weeks post-TQD
Title
Smoking reduction
Description
Smoking reduction as measured by number of cpd measured by phone-based self-report
Time Frame
12 weeks post-TQD
Title
Smoking reduction
Description
Smoking reduction as measured by number of cpd measured by phone-based self-report
Time Frame
26 weeks post-TQD
Title
Changes in stress
Description
Change in self-reported measures of stress
Time Frame
Baseline to 2-week and 12-week post TQD
Title
Changes in anxiety
Description
Change in self-reported measures of anxiety
Time Frame
Baseline to 2-week and 12-week post TQD
Title
Changes in depression
Description
Change in self-reported measures of depression
Time Frame
Baseline to 2-week and 12-week post TQD
Title
Changes in relapse predictors
Description
Changes in self-reported measures on repeated non-standardized single-item question on stress, urges, and confidence assessed by phone
Time Frame
Baseline to 1-week post-TQD, 2-week post-TQD, 6-week post-TQD, 12-week post-TQD, and 26-week post-TQD
Title
Feasibility: attendance records
Description
Feasibility as measured by attendance and completion of STQ and QL assessed by attendance records taken instructors during phone sessions.
Time Frame
Up to 12 weeks post-TQD
Title
Feasibility: website usage
Description
Feasibility as measured by website usage by electronically recording login and using a site-based timer to record time accessing the site through each intervention
Time Frame
Up to 12 weeks post-TQD
Title
Feasibility: course evaluation
Description
Feasibility as measured by course evaluation
Time Frame
Up to 12 weeks post-TQD
Title
Feasibility: demographics
Description
Feasibility as measured by demographics of patients at DSCP
Time Frame
12-weeks post-TQD
Title
Feasibility: Behavioral intervention used
Description
Feasibility as measured by behavioral intervention assignment
Time Frame
12 weeks post-TQD
Title
Feasibility: Attendance at DSCP appointments
Description
Feasibility as measured by attendance at DSCP appointments
Time Frame
12 weeks post-TQD
Title
Feasibility: Referral routes to DSCP
Description
Feasibility as measured by referral routes to DSCP
Time Frame
Baseline
Title
Feasibility: Side effects
Description
Feasibility as measured by side effects, as measured by phone assessment
Time Frame
1-week post-TQD, 2-week post-TQD, and 6-week post-TQD
Title
Feasibility: medication adherence
Description
Feasibility as measured by medication adherence, as measured by phone assessment
Time Frame
1-week post-TQD, 2-week post-TQD, 6-week post-TQD, and 26-week post-TQD
Title
Feasibility: mindfulness practices
Description
Feasibility as measured by non-standardized phone-based self-report of number of times mindfulness practices are used by experimental group
Time Frame
1-week post-TQD, 2-week post-TQD, 6-week post-TQD, and 26-week post-TQD
Title
Feasibility: meditation time
Description
Feasibility as measured by non-standardized phone-based self-report of time spent meditating by experimental group
Time Frame
1-week post-TQD, 2-week post-TQD, 6-week post-TQD, and 26-week post-TQD
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient being treated at Duke Smoking Cessation Program for tobacco use
Age 18 years or older
Actively smoking 5 or more cigarettes per day for at least one year
Fluency in spoken and written English
Willing to set a quit date within 2 weeks
Access to a smart phone or internet and telephone
Willingness to watch 3 videos on computer, receive 5 counseling calls, and attend investigational visits.
Exclusion Criteria:
CO test under 7 ppm during initial screening
8 or above on the Alcohol Use Disorders Identification Test (AUDIT-10)
6 or above on Drug Abuse Screening Test (DAST-10)
3 or above on Patient Health Questionnaire (PHQ-2) Depression Scale
Daily use of a second form of tobacco or nicotine (e.g. e-cigarettes, cigars, chewing tobacco, snuff)
Current use of a smoking cessation medication (e.g. nicotine replacement, Varenicline, Bupropion)
Intolerable side effects related to, refusal to take, or medical contraindication with nicotine patch
Symptomatic cognitive or emotive disorder such as untreated schizophrenia, severe untreated depression, or severe untreated anxiety. This is determined by clinical assessment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James M Davis, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke Center for Smoking Cessation
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Study on Sit to Quit Phone Intervention
We'll reach out to this number within 24 hrs